Preview

Кардиология

Расширенный поиск
Доступ открыт Открытый доступ  Доступ закрыт Доступ платный или только для Подписчиков

Тестостерон и хроническая сердечная недостаточность

https://doi.org/10.18087/cardio.2022.7.n1242

Полный текст:

Аннотация

В статье обобщены современные данные о взаимосвязи между уровнем тестостерона и хронической сердечной недостаточностью (ХСН). Рассмотрены ключевые публикации, посвященные вопросам распространенности дефицита тестостерона у больных с ХСН, влияния эндогенного и экзогенного тестостерона на сердечно-сосудистую систему, связи уровня тестостерона с тяжестью ХСН, прогнозом и эффективностью интервенционных методов лечения при ХСН.

 

Об авторах

Т. Н. Енина
ФГБНУ "Томский национальный исследовательский медицинский центр РАН", Томск
Россия

д.м.н., ведущий научный сотрудник

 



В. А. Кузнецов
ФГБНУ "Томский национальный исследовательский медицинский центр РАН", Томск
Россия

доктор медицинских наук, профессор,  заслуженный деятель науки РФ, научный консультант



А. М. Солдатова
ФГБНУ "Томский национальный исследовательский медицинский центр РАН", Томск
Россия

кандидат медицинских наук, научный сотрудник



Список литературы

1. Cruz-Topete D, Dominic P, Stokes KY. Uncovering sex-specific mechanisms of action of testosterone and redox balance. Redox Biology. 2020;31:101490. DOI: 10.1016/j.redox.2020.101490

2. Chignalia AZ, Schuldt EZ, Camargo LL, Montezano AC, Callera GE, Laurindo FR et al. Testosterone Induces Vascular Smooth Muscle Cell Migration by NADPH Oxidase and c-Src–Dependent Pathways. Hypertension. 2012;59(6):1263–71. DOI: 10.1161/HYPERTENSIONAHA.111.180620

3. Pingili AK, Kara M, Khan NS, Estes AM, Lin Z, Li W et al. 6β-Hydroxytestosterone, a Cytochrome P450 1B1 Metabolite of Testosterone, Contributes to Angiotensin II–Induced Hypertension and Its Pathogenesis in Male Mice. Hypertension. 2015;65(6):1279–87. DOI: 10.1161/HYPERTENSIONAHA.115.05396

4. Zhang L, Wu S, Hong L, Xing X, Lai W. Testosterone suppresses oxidative stress via androgen receptor-independent pathway in murine cardiomyocytes. Molecular Medicine Reports. 2011;11:1183–1188. DOI: 10.3892/mmr.2011.539

5. Xiao F-Y, Nheu L, Komesaroff P, Ling S. Testosterone protects cardiac myocytes from superoxide injury via NF-κB signalling pathways. Life Sciences. 2015;133:45–52. DOI: 10.1016/j.lfs.2015.05.009

6. Foradori CD, Weiser MJ, Handa RJ. Non-genomic actions of androgens. Frontiers in Neuroendocrinology. 2008;29(2):169–81. DOI: 10.1016/j.yfrne.2007.10.005

7. Lorigo M, Mariana M, Lemos MC, Cairrao E. Vascular mechanisms of testosterone: The non-genomic point of view. The Journal of Steroid Biochemistry and Molecular Biology. 2020;196:105496. DOI: 10.1016/j.jsbmb.2019.105496

8. Thirumalai A, Rubinow KB, Page ST. An update on testosterone, HDL and cardiovascular risk in men. Clinical Lipidology. 2015;10(3):251– 8. DOI: 10.2217/clp.15.10

9. Coward R, Carson C, McBride J. Diagnosis and management of testosterone deficiency. Asian Journal of Andrology. 2015;17(2):177–86. DOI: 10.4103/1008-682X.143317

10. Harman SM, Metter EJ, Tobin JD, Pearson J, Blackman MR. Longitudinal Effects of Aging on Serum Total and Free Testosterone Levels in Healthy Men. Baltimore Longitudinal Study of Aging. The Journal of Clinical Endocrinology and Metabolism. 2001;86(2):724–31. DOI: 10.1210/jcem.86.2.7219

11. Мельниченко Г.А., Шестакова М.В., Роживанов Р.В., Терехова А.Л., Зилов А.В., Ладыгина Д.О. и др. Рекомендации по диагностике и лечению дефицита тестостерона (гипогонадизма) у мужчин. Сахарный диабет. 2017;20(2):151-60. DOI: 10.14341/7884

12. Salonia A, Bettocchi C, Carvalho J, Corona G, Jones TH, Kadioglu A et al. EAU Guidelines on Sexus and Reproductive Health. Av. at: https://uroweb.org/wp-content/uploads/EAU-Guidelines-on-Sexual-and-Reproductive-Health-2020.pdf. 2020.

13. Bhasin S, Brito JP, Cunningham GR, Hayes FJ, Hodis HN, Matsumoto AM et al. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. The Journal of Clinical Endocrinology & Metabolism. 2018;103(5):1715–44. DOI: 10.1210/jc.2018-00229

14. Araujo AB, Kupelian V, Page ST, Handelsman DJ, Bremner WJ, McKinlay JB. Sex Steroids and All-Cause and Cause-Specific Mortality in Men. Archives of Internal Medicine. 2007;167(12):1252–60. DOI: 10.1001/archinte.167.12.1252

15. Kirby M, Hackett G, Ramachandran S. Testosterone and the Heart. European Cardiology Review. 2019;14(2):103–10. DOI: 10.15420/ecr.2019.13.1

16. Jankowska EA, Tkaczyszyn M, Kalicińska E, Banasiak W, Ponikowski P. Testosterone deficiency in men with heart failure: pathophysiology and its clinical, prognostic and therapeutic implications. Kardiologia Polska. 2014;72(5):403–9. DOI: 10.5603/KP.a2014.0025

17. Khaw K-T, Dowsett M, Folkerd E, Bingham S, Wareham N, Luben R et al. Endogenous testosterone and mortality due to all causes, cardiovascular disease, and cancer in men: European prospective investigation into cancer in Norfolk (EPIC-Norfolk) Prospective Population Study. Circulation. 2007;116(23):2694–701. DOI: 10.1161/CIRCULATIONAHA.107.719005

18. Araujo AB, Dixon JM, Suarez EA, Murad MH, Guey LT, Wittert GA. Endogenous Testosterone and Mortality in Men: A Systematic Review and Meta-Analysis. The Journal of Clinical Endocrinology & Metabolism. 2011;96(10):3007–19. DOI: 10.1210/jc.2011-1137

19. Corona G, Rastrelli G, Monami M, Guay A, Buvat J, Sforza A et al. Hypogonadism as a risk factor for cardiovascular mortality in men: a meta-analytic study. European Journal of Endocrinology. 2011;165(5):687–701. DOI: 10.1530/EJE-11-0447

20. Laughlin GA, Barrett-Connor E, Bergstrom J. Low Serum Testosterone and Mortality in Older Men. The Journal of Clinical Endocrinology & Metabolism. 2008;93(1):68–75. DOI: 10.1210/jc.2007-1792

21. Ohlsson C, Barrett-Connor E, Bhasin S, Orwoll E, Labrie F, Karlsson MK et al. High Serum Testosterone Is Associated With Reduced Risk of Cardiovascular Events in Elderly Men. Journal of the American College of Cardiology. 2011;58(16):1674–81. DOI: 10.1016/j.jacc.2011.07.019

22. Chan YX, Knuiman MW, Hung J, Divitini ML, Beilby JP, Handelsman DJ et al. Neutral associations of testosterone, dihydrotestosterone and estradiol with fatal and non-fatal cardiovascular events, and mortality in men aged 17-97 years. Clinical Endocrinology. 2016;85(4):575–82. DOI: 10.1111/cen.13089

23. Collet T-H, Ewing SK, Ensrud KE, Laughlin GA, Hoffman AR, Varosy PD et al. Endogenous Testosterone Levels and the Risk of Incident Cardiovascular Events in Elderly Men: The MrOS Prospective Study. Journal of the Endocrine Society. 2020;4(5):bvaa038. DOI: 10.1210/jendso/bvaa038

24. Yeap BB, Alfonso H, Chubb SAP, Handelsman DJ, Hankey GJ, Almeida OP et al. In Older Men an Optimal Plasma Testosterone Is Associated With Reduced All-Cause Mortality and Higher Dihydrotestosterone With Reduced Ischemic Heart Disease Mortality, While Estradiol Levels Do Not Predict Mortality. The Journal of Clinical Endocrinology & Metabolism. 2014;99(1):E9–18. DOI: 10.1210/jc.2013-3272

25. Yeap B. Testosterone and its metabolites: differential associations with cardiovascular and cerebrovascular events in men. Asian Journal of Andrology. 2018;20(2):109–14. DOI: 10.4103/aja.aja_50_17

26. Wang W, Jiang T, Li C, Chen J, Cao K, Qi L-W et al. Will testosterone replacement therapy become a new treatment of chronic heart failure? A review based on 8 clinical trials. Journal of Thoracic Disease. 2016;8(5):E269–77. DOI: 10.21037/jtd.2016.03.39

27. Yoshihisa A, Suzuki S, Sato Y, Kanno Y, Abe S, Miyata M et al. Relation of Testosterone Levels to Mortality in Men With Heart Failure. The American Journal of Cardiology. 2018;121(11):1321–7. DOI: 10.1016/j.amjcard.2018.01.052

28. Mehra MR. Fat, Cachexia, and the Right Ventricle in Heart Failure. Journal of the American College of Cardiology. 2013;62(18):1671–3. DOI: 10.1016/j.jacc.2013.07.021

29. Nguyen AB, Imamura T, Besser S, Rodgers D, Chung B, Raikhelkar J et al. Metabolic Dysfunction in Continuous‐Flow Left Ventricular Assist Devices Patients and Outcomes. Journal of the American Heart Association. 2019;8(22):e013278. DOI: 10.1161/JAHA.119.013278

30. Naderi N, Heidarali M, Barzegari F, Ghadrdoost B, Amin A, Taghavi S. Hormonal Profile in Patients With Dilated Cardiomyopathy. Research in Cardiovascular Medicine. 2015;4(3):e27631. DOI: 10.5812/ cardiovascmed.27631v2

31. Iellamo F, Volterrani M, Caminiti G, Karam R, Massaro R, Fini M et al. Testosterone Therapy in Women With Chronic Heart Failure. Journal of the American College of Cardiology. 2010;56(16):1310–6. DOI: 10.1016/j.jacc.2010.03.090

32. Xu L, Freeman G, Cowling BJ, Schooling CM. Testosterone therapy and cardiovascular events among men: a systematic review and meta-analysis of placebo-controlled randomized trials. BMC medicine. 2013;11:108. DOI: 10.1186/1741-7015-11-108

33. König CS, Balabani S, Hackett GI, Strange RC, Ramachandran S. Testosterone Therapy: An Assessment of the Clinical Consequences of Changes in Hematocrit and Blood Flow Characteristics. Sexual Medicine Reviews. 2019;7(4):650–60. DOI: 10.1016/j.sxmr.2019.01.003

34. Malkin CJ, Morris PD, Pugh PJ, English KM, Channer KS. Effect of testosterone therapy on QT dispersion in men with heart failure. The American Journal of Cardiology. 2003;92(10):1241–3. DOI: 10.1016/j.amjcard.2003.07.044

35. Schwartz JB, Volterrani M, Caminiti G, Marazzi G, Fini M, Rosano GMC et al. Effects of testosterone on the Q-T Interval in older men and older women with chronic heart failure. International Journal of Andrology. 2011;34(5 Pt 2):e415–21. DOI: 10.1111/j.1365-2605.2011.01163.x

36. Zeller T, Schnabel RB, Appelbaum S, Ojeda F, Berisha F, Schulte-Steinberg B et al. Low testosterone levels are predictive for incident atrial fibrillation and ischaemic stroke in men, but protective in women – results from the FINRISK study. European Journal of Preventive Cardiology. 2018;25(11):1133–9. DOI: 10.1177/2047487318778346

37. Berger D, Folsom AR, Schreiner PJ, Chen LY, Michos ED, O’Neal WT et al. Plasma total testosterone and risk of incident atrial fibrillation: The Atherosclerosis Risk in Communities (ARIC) study. Maturitas. 2019;125:5–10. DOI: 10.1016/j.maturitas.2019.03.015

38. Енина Т.Н., Кузнецов В.А., Солдатова А.М., Петелина Т.И., Криночкин Д.В., Дьячков С.М. и др. Взаимосвязь уровня половых гормонов у мужчин с ответом на сердечную ресинхронизирующую терапию. Кардиология. 2018;58(S7):24–35. DOI: 10.18087/cardio.2464

39. Lucia C de, Eguchi A, Koch WJ. New Insights in Cardiac β-Adrenergic Signaling During Heart Failure and Aging. Frontiers in Pharmacology. 2018;9:904. DOI: 10.3389/fphar.2018.00904

40. Nguyen M-N, Kiriazis H, Ruggiero D, Gao X-M, Su Y, Jian A et al. Spontaneous ventricular tachyarrhythmias in β2-adrenoceptor transgenic mice in relation to cardiac interstitial fibrosis. American Journal of Physiology-Heart and Circulatory Physiology. 2015;309(5):H946– 57. DOI: 10.1152/ajpheart.00405.2015

41. Sun J, Fu L, Tang X, Han Y, Ma D, Cao J et al. Testosterone modulation of cardiac β-adrenergic signals in a rat model of heart failure. General and Comparative Endocrinology. 2011;172(3):518–25. DOI: 10.1016/j.ygcen.2011.04.019

42. Cohn JN, Levine TB, Olivari MT, Garberg V, Lura D, Francis GS et al. Plasma Norepinephrine as a Guide to Prognosis in Patients with Chronic Congestive Heart Failure. New England Journal of Medicine. 1984;311(13):819–23. DOI: 10.1056/NEJM198409273111303

43. Han Y, Fu L, Sun W, Cao J, Xie R, Zhou P et al. Neuroprotective effects of testosterone upon cardiac sympathetic function in rats with induced heart failure. European Journal of Pharmacology. 2009;619(1–3):68–74. DOI: 10.1016/j.ejphar.2009.07.023

44. Vergaro G, Aimo A, Prontera C, Ghionzoli N, Arzilli C, Zyw L et al. Sympathetic and renin-angiotensin-aldosterone system activation in heart failure with preserved, mid-range and reduced ejection fraction. International Journal of Cardiology. 2019;296:91–7. DOI: 10.1016/j.ijcard.2019.08.040

45. Toma M, McAlister FA, Coglianese EE, Vidi V, Vasaiwala S, Bakal JA et al. Testosterone Supplementation in Heart Failure: A Meta-Analysis. Circulation: Heart Failure. 2012;5(3):315–21. DOI: 10.1161/CIRCHEARTFAILURE.111.965632

46. Tao J, Liu X, Bai W. Testosterone Supplementation in Patients With Chronic Heart Failure: A Meta-Analysis of Randomized Controlled Trials. Frontiers in Endocrinology. 2020;11:110. DOI: 10.3389/fendo.2020.00110

47. Schmid FA, Schlager O, Keller P, Seifert B, Huang R, Fröhlich GM et al. Prognostic value of long-term blood pressure changes in patients with chronic heart failure. European Journal of Heart Failure. 2017;19(7):837–42. DOI: 10.1002/ejhf.805

48. Pugh P, Jones TH, Channer KS. Acute haemodynamic effects of testosterone in men with chronic heart failure. European Heart Journal. 2003;24(10):909–15. DOI: 10.1016/S0195-668X(03)00083-6

49. Arcopinto M, Salzano A, Bossone E, Ferrara F, Bobbio E, Sirico D et al. Multiple hormone deficiencies in chronic heart failure. International Journal of Cardiology. 2015;184:421–3. DOI: 10.1016/j.ijcard.2015.02.055

50. Salzano A, Marra AM, Arcopinto M, D’Assante R, Triggiani V, Coscioni E et al. Combined effects of growth hormone and testosterone replacement treatment in heart failure. ESC Heart Failure. 2019;6(6):1216–21. DOI: 10.1002/ehf2.12520

51. Basaria S, Coviello AD, Travison TG, Storer TW, Farwell WR, Jette AM et al. Adverse Events Associated with Testosterone Administration. New England Journal of Medicine. 2010;363(2):109–22. DOI: 10.1056/NEJMoa1000485

52. Vigen R, O’Donnell CI, Barón AE, Grunwald GK, Maddox TM, Bradley SM et al. Association of Testosterone Therapy With Mortality, Myocardial Infarction, and Stroke in Men With Low Testosterone Levels. JAMA. 2013;310(17):1829. DOI: 10.1001/jama.2013.280386

53. Finkle WD, Greenland S, Ridgeway GK, Adams JL, Frasco MA, Cook MB et al. Increased Risk of Non-Fatal Myocardial Infarction Following Testosterone Therapy Prescription in Men. PLoS ONE. 2014;9(1):e85805. DOI: 10.1371/journal.pone.0085805

54. Elagizi A, Köhler TS, Lavie CJ. Testosterone and Cardiovascular Health. Mayo Clinic Proceedings. 2018;93(1):83–100. DOI: 10.1016/j.mayocp.2017.11.006

55. US Food and Drug Administration. FDA Drug Safety Communication: FDA cautions about using testosterone products for low testosterone due to aging; requires labeling change to inform of possible increased risk of heart attack and stroke with use. FDA. 2019; [Av. at: https://www.fda.gov/drugs/drug-safety-and-availability/fda-drugsafety-communication-fda-cautions-about-using-testosterone-products-low-testosterone-due]

56. Simsek E, Kilic S, Kemal HS, Nalbantgil S, Ozturk P, Yildirim I et al. Effect of Testosterone Level on Mortality in Patients With Left Ventricular Assist Device. Transplantation Proceedings. 2019;51(10):3418–23. DOI: 10.1016/j.transproceed.2019.07.028


Рецензия

Для цитирования:


Енина Т.Н., Кузнецов В.А., Солдатова А.М. Тестостерон и хроническая сердечная недостаточность. Кардиология. 2022;62(7):61-67. https://doi.org/10.18087/cardio.2022.7.n1242

For citation:


Enina T.N., Kuznetsov V.A., Soldatova A.M. Testosterone and congestive heart failure. Kardiologiia. 2022;62(7):61-67. (In Russ.) https://doi.org/10.18087/cardio.2022.7.n1242

Просмотров: 243


ISSN 0022-9040 (Print)
ISSN 2412-5660 (Online)